Intracellular and extracellular targets as mechanisms of cancer therapy by nanomaterials in relation to their physicochemical properties

Abstract

Cancer nanomedicine has evolved in recent years and is only expected to increase due to the ease with which nanomaterials (NMs) may be manipulated to the advantage of the cancer patient. The success of nanomedicine is dependent on the cell death mechanism, which in turn is dependent on the organelle initially targeted. The success of cancer nanomedicine is also dependent on other cellular mechanisms such as the induction of autophagy dysfunction, manipulation of the tumor microenvironment (TME) and secretome or induction of host immune responses. Current cancer phototherapies for example, photothermal‐ or photodynamic therapies as well as radio enhancement also form a major part of cancer nanomedicine. In general, cancer nanomedicine may be grouped into those NMs exhibiting inherent anti‐cancer properties that is, self‐therapeutic NMs (Group 1), NMs leading to localization of phototherapies or radio‐enhancement (Group 2), and NMs as nanocarriers in the absence or presence of external radiation (Group 3). The recent advances of these three groups, together with their advantages and disadvantages as well as their cellular mechanisms and ultimate outcomes are summarized in this review. By exploiting these different intracellular mechanisms involved in initiating cell death pathways, it is possible to synthesize NMs that may have the desirable characteristics to maximize their efficacy in cancer therapy. Therefore, a summary of these important physicochemical characteristics is also presented that need to be considered for optimal cancer cell targeting and initiation of mechanisms that will lead to cancerous cell death. This article is categorized under: Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease Toxicology and Regulatory Issues in Nanomedicine > Toxicology of Nanomaterials Toxicology and Regulatory Issues in Nanomedicine > Regulatory and Policy Issues in Nanomedicine

Systematic Review of Cancer Targeting by Nanoparticles Revealed a Global Association between Accumulation in Tumors and Spleen

“…Typically, cancers recruit other cells to support their growth and repress the immune system including cancer-associated fibroblasts, microphages, myeloid derives suppressor cells, and Treg lymphocytes [ 78 , 79 ]. All these changes can be explored for the specific targeting of cancer vs. normal tissues by targeting both intracellular and extracellular targets [ 4 , 29 , 77 , 80 , 81 , 82 , 83 , 84 , 85 , 86 ].…”

Application of phototherapeutic-based nanoparticles in colorectal cancer

“…Nano drugs have the ability to kill tumor cells by initially targeting organelles, resulting in a series of subsequent reactions 48 . By targeting specific receptors of a specific organelle, corresponding signaling network is activated, then the protein expression and activation level of the signaling pathway are up-regulated or down-regulated.…”

Biogenic Selenium Nanoparticles in Biomedical Sciences: Properties, Current Trends, Novel Opportunities and Emerging Challenges in Theranostic Nanomedicine

“…Nanotechnology deals with the design of particles, tools and devices in the range between 1 and 100 nm in size with specific functions at the cellular, atomic and molecular levels [ 1 , 2 ]. Nanomedicine is a relatively new but fast-developing field that can potentially elicit a major impact on human health by combining nanotechnology-based techniques and methods with biomedical and pharmaceutical sciences [ 3 , 4 , 5 , 6 , 7 ]. Thus, nanotechnology can remarkably assist the therapy, diagnosis, monitoring and control of biological systems for future development of personalized medicine with tailored and optimized treatments [ 8 , 9 , 10 ].…”